Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) have earned an average recommendation of "Buy" from the five research firms that are currently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $3.55.
Several equities analysts have recently commented on the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $2.00 price objective on shares of Lucid Diagnostics in a report on Thursday, May 15th. Needham & Company LLC reaffirmed a "buy" rating and set a $3.00 target price on shares of Lucid Diagnostics in a research note on Wednesday, May 14th. Wall Street Zen downgraded shares of Lucid Diagnostics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Ascendiant Capital Markets upped their target price on shares of Lucid Diagnostics from $7.50 to $7.75 and gave the stock a "buy" rating in a research note on Friday, June 6th. Finally, BTIG Research set a $2.00 target price on shares of Lucid Diagnostics in a research note on Tuesday, March 25th.
View Our Latest Analysis on LUCD
Lucid Diagnostics Price Performance
Shares of LUCD stock traded up $0.03 during trading hours on Friday, hitting $1.17. The company had a trading volume of 1,193,177 shares, compared to its average volume of 692,408. The company's fifty day moving average is $1.25 and its 200 day moving average is $1.23. Lucid Diagnostics has a fifty-two week low of $0.72 and a fifty-two week high of $1.80. The stock has a market capitalization of $126.58 million, a PE ratio of -0.87 and a beta of 1.23.
Institutional Investors Weigh In On Lucid Diagnostics
A number of large investors have recently modified their holdings of the company. Alyeska Investment Group L.P. purchased a new position in shares of Lucid Diagnostics in the 1st quarter valued at $2,813,000. Ghisallo Capital Management LLC acquired a new stake in Lucid Diagnostics during the 1st quarter worth $629,000. Geode Capital Management LLC boosted its stake in Lucid Diagnostics by 30.9% during the 4th quarter. Geode Capital Management LLC now owns 279,504 shares of the company's stock worth $229,000 after purchasing an additional 65,964 shares during the period. XML Financial LLC acquired a new stake in Lucid Diagnostics during the 1st quarter worth $266,000. Finally, Lido Advisors LLC boosted its stake in Lucid Diagnostics by 40.0% during the 4th quarter. Lido Advisors LLC now owns 140,016 shares of the company's stock worth $115,000 after purchasing an additional 40,000 shares during the period. 74.01% of the stock is owned by hedge funds and other institutional investors.
Lucid Diagnostics Company Profile
(
Get Free ReportLucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
See Also
Before you consider Lucid Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lucid Diagnostics wasn't on the list.
While Lucid Diagnostics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
